ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
120.261,34
0,53%
S&P 500
5.487,03
0,25%
US Dollar vs BRL
5,4237
0,00%
Bitcoin
65.633,04
1,05%
Brent Oil
84,735
0,05%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Ionis Pharmaceuticals Inc (IONS)

  7. Ionis Pharmaceuticals Inc (IONS) Notícias

IONS Ionis Pharmaceuticals Inc

40,64
0,00 (0,00%)
Pré-mercado
Última atualização: 05:00:07
Atrasado em 15 minutos
Nome da Ação Código da Ação Bolsa de Valores Tipo de Ativo
Ionis Pharmaceuticals Inc IONS NASDAQ Ordinária
  Variação do Dia (p) Variação do Dia % Último Preço Hora
Upgrade Icon
0,00 0,00% 40,64 05:00:07
Preço de Abertura Preço Mínimo Preço Máximo Fech. Hoje Fech. Anterior
40,64
mais cotações »

Notícias Recentes

Data Hora Fonte Título
18/06/202408:00PRNUSIonis announces expanded licensing agreement with Otsuka in..
17/06/202417:09PRNUSIonis to present at TD Cowen Genetic Medicines & RNA Summit
31/05/202408:00PRNUSIonis presents positive results from OASIS-HAE and OASISplus..
28/05/202408:00PRNUSIonis to hold donidalorsen Phase 3 data webcast
23/05/202408:00PRNUSNew data from the Phase 3 NEURO-TTRansform study evaluating..
16/05/202408:30GLOBEBiogen and Ionis Announce Topline Phase 1/2 Study Results of..
16/05/202408:30PRNUSIonis and Biogen Announce Topline Phase 1/2 Study Results of..
16/05/202408:00PRNUSIonis announces positive topline results from Phase 1/2a..
15/05/202408:05PRNUSIonis to host 2024 virtual Annual Meeting of Stockholders
07/05/202408:00PRNUSIonis reports first quarter 2024 financial results
25/04/202408:00PRNUSIonis Publishes 2023 Corporate Responsibility Report
23/04/202408:05PRNUSIonis to hold first quarter 2024 financial results webcast
07/04/202410:48PRNUSIonis presents positive results from Phase 3 Balance study..
01/04/202408:05PRNUSIonis to present at upcoming investor conferences
28/03/202408:05PRNUSIonis to hold olezarsen Phase 3 data webcast
25/03/202409:18PRNUSPositive olezarsen Phase 3 data in familial chylomicronemia..
13/03/202408:00PRNUSIonis announces positive results from Phase 2 study of..
06/03/202409:30GLOBENew Biomarker Data Add Further Evidence Supporting the..
29/02/202411:05PRNUSIonis announces new chief global product strategy officer to..
28/02/202409:05PRNUSIonis to present at upcoming investor conferences
21/02/202409:00PRNUSIonis reports fourth quarter and full year 2023 financial..
15/02/202409:00PRNUSOlezarsen receives Orphan Drug designation from U.S. FDA for..
08/02/202409:00PRNUSEplontersen granted U.S. FDA Fast Track designation for..
07/02/202409:05PRNUSIonis to hold fourth quarter and full year 2023 financial..
22/01/202409:00PRNUSIonis announces positive topline results from Phase 3..
08/01/202409:03PRNUSIonis poised for continued momentum in 2024 with product..
21/12/202321:38DJNIonis Pharmaceuticals, AstraZeneca Get FDA Approval for Rare..
21/12/202320:55PRNUSWAINUA™ (eplontersen) granted regulatory approval in the..
20/12/202309:05PRNUSIonis to present at 42nd Annual J.P. Morgan Healthcare..
18/12/202318:01PRNUSIonis announces European licensing agreement with Otsuka for..
14/12/202318:05PRNUSIonis announces the appointment of Michael Yang to Board of..
16/11/202310:00GLOBEPraxis Precision Medicines Receives PRIME Designation from..
11/11/202313:30PRNUSIonis shares positive clinical update from ongoing trial of..
09/11/202314:42PRNUSIonis presents positive two-year results from the Phase 2..
03/11/202308:05PRNUSIonis to present at upcoming investor conferences
02/11/202308:00PRNUSIonis reports third quarter 2023 financial results
19/10/202308:05PRNUSIonis to hold third quarter 2023 financial results webcast
04/10/202308:00PRNUSIonis shares significant business and pipeline progress at..
02/10/202314:17GLOBEPraxis Precision Medicines Provides Portfolio Update at 2023..
28/09/202313:02PRNUSEplontersen Phase 3 results published in JAMA show..
27/09/202308:59DJNIonis, Roche Set New Pact Targeting Alzheimer's,..
27/09/202308:00PRNUSIonis enters agreement with Roche for two novel RNA-targeted..
26/09/202308:00PRNUSIonis announces positive olezarsen topline results from..
12/09/202308:05PRNUSIonis to host investor and analyst day event
30/08/202308:05PRNUSIonis to present at upcoming investor conferences
09/08/202308:00PRNUSIonis reports second quarter 2023 financial results
03/08/202308:05PRNUSIonis enters collaboration to advance next generation..
31/07/202308:05PRNUSIonis completes enrollment in landmark Phase 3..
28/07/202308:05PRNUSIonis expands eplontersen agreement with AstraZeneca to..
26/07/202308:05PRNUSIonis to hold second quarter 2023 financial results webcast

Seu Histórico Recente

NASDAQ
IONS
Ionis Pharmaceuticals
ASX
W2V
Way 2 Vat
BIT
I05665
Banca Imi
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados